Utilization patterns and characteristics of users of biologic anti-inflammatory agents in a large, US commercially insured population
Aaron B Mendelsohn, Young Hee Nam, James Marshall, Cara L McDermott, Bharati Kochar, Michael D Kappelman, Jeffrey S Brown, Catherine M Lockhart, Aaron B Mendelsohn, Young Hee Nam, James Marshall, Cara L McDermott, Bharati Kochar, Michael D Kappelman, Jeffrey S Brown, Catherine M Lockhart
Abstract
We report utilization patterns and characteristics of patients treated with biologic anti-inflammatory agents in a large commercially insured patient population in the United States. We identified adult (age ≥18 years) patients receiving biologic anti-inflammatory agents between 1 January 2012 and 31 March 2019 across the five Research Partners in the Biologic and Biosimilars Collective Intelligence Consortium's Distributed Research Network. We examined the number of incident use episodes for each biologic, as well as patient demographic and clinical characteristics. Curated data and analytic tools from the Food and Drug Administration's Sentinel System were used to perform the analyses. We identified 90,360 incident episodes of tumor necrosis factor-alpha inhibitors (TNFi) and 70,506 incident episodes of non-TNFi medications. Adalimumab was the most common TNFi drug (47% of all TNFi episodes) and showed a steady increase in utilization during the study period compared to other TNFi agents. Rituximab was the most commonly initiated non-TNFi medication (44% of non-TNFi episodes). Other non-TNFi agents, namely, ustekinumab, vedolizumab, and secukinumab, demonstrated notable increases in utilization over time. Biosimilar use was limited; we observed 653 incident episodes for infliximab-dyyb and 39 incident episodes for infliximab-abda. As more biologics enter the market, greater variation in the use of biologics with similar indications and between biologic originators and biosimilars is anticipated. Because information on efficacy and safety at the time of drug approval is limited, post-marketing surveillance and research is needed to monitor medication safety and evaluate effectiveness between biologic drugs using real-world data.
Keywords: anti-inflammatory; biologics; biosimilars; dermatology; gastroenterology; patterns; rheumatology; treatment; trends; utilization.
Conflict of interest statement
Michael Kappelman is a consultant to Janssen, AbbVie and Takeda and receives research support from Janssen and AbbVie. All other authors have no competing interests.
© 2020 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics.
Figures
References
- Falit BP, Singh SC, Brennan TA. Biosimilar competition in the Unites States: statutory incentives, payers, and pharmacy benefit managers. Health Aff. 2015;34(2):294‐301.
- Crespi‐Lofton J, Skelton JB. The growing role of biologics and biosimilars in the United States: perspectives from the APhA Biologics and Biosimilars Stakeholder Conference. J Am Pharm Assoc. 2017;57(5):e15‐e27.
- US Food and Drug Administration . Biosimilar product information. . Accessed 17 January 2020
- Ingrasciotta Y, Cutroneo PM, Marcianò I, Giezen T, Atzeni F, Trifirò G. Safety of biologics, including biosimilars: perspectives on current status and future direction. Drug Saf. 2018;41:1013‐1022.
- Giezen TJ, Mantel‐Teeuwisse AK, Straus SMJ, Schellekens H, Leufkens HGM, Egberts ACG. Safety‐related regulatory actions for biologicals approved in the United States and the European Union. JAMA. 2008;300(16):1887‐1896.
- US Food and Drug Administration . FDA’s Sentinel Initiative. Available at . Accessed 29 March 2020
- Platt R, Brown JS, Robb M, et al. The FDA sentinel initiative ‐ an evolving national resource. N Engl J Med. 2018;379(22):2091‐2093.
- Ball R, Robb M, Anderson SA, Dal Pan G. The FDA's sentinel initiative–A comprehensive approach to medical product surveillance. Clin Pharmacol Ther. 2016;99(3):265‐268.
- The Sentinel Operations Center . Surveillance Tools: Routine Querying Tools (Modular Programs). . Accessed 17 January, 2020
- Gagne JJ, Popovic JR, Nguyen M, et al. Evaluation of switching patterns in FDA’s Sentinel System: A New Tool to Assess Generic Drugs. Drug Saf. 2018;41:1313‐1323.
Source: PubMed